Prioritizing multipurpose prevention technology development and investments using a target product profile

Antiviral Research

Volumn 100, Issue SUPPL., 2013, Pages

  Romano, Joe ^a   Manning, Judy ^b   Hemmerling, Anke ^c,d   McGrory, Elizabeth ^e   Young Holt, Bethany ^c  

^a NWJ Group LLC   (United States)

^b US Agency for International Development   (United States)

^c Public Health Institute ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Independent Consultant   (United States)

Author keywords

Contraception; HIV prevention; Multipurpose prevention technologies; STI prevention

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CONTRACEPTIVE AGENT; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL PLUS ETONOGESTREL; LEVONORGESTREL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CONTRACEPTION; DRUG DEVELOPMENT; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVESTMENT; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SUSTAINED DRUG RELEASE; UNPLANNED PREGNANCY; VAGINA RING; FEMALE CONTRACEPTIVE DEVICE; HEALTH CARE NEED; HUMAN IMMUNODEFICIENCY VIRUS; MULTIPURPOSE PREVENTION TECHNOLOGY; PRODUCT DEVELOPMENT; PUBLIC HEALTH; TECHNOLOGY; ARTICLE; EQUIPMENT; FEMALE; HIV PREVENTION; INFECTION CONTROL; MALE; METHODOLOGY; MULTIPURPOSE PREVENTION TECHNOLOGIES; PREGNANCY; STI PREVENTION;

CONTRACEPTION; HIV PREVENTION; MULTIPURPOSE PREVENTION TECHNOLOGIES; STI PREVENTION;

COMMUNICABLE DISEASE CONTROL; CONTRACEPTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; SEXUALLY TRANSMITTED DISEASES;

EID: 84890117418     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.016     Document Type: Review

References (35)

1. B. Affandi Long-acting progestogens Best Pract. Res. Clin. Obstet. Gynaecol. 16 2002 169 179 (Pubitemid 41123413)
2. Andrews, C., Gettie, A., Russell-Lodrique, K., et al., 2013. Long acting parenteral formulation of GSK 1265744 protects macaques against repeated inter-rectal challenges with SHIV. 20th CROI, Abstract 24LB, March 3-6, 2013, Atlanta, GA. http://www.retroconference.org/2013b/Abstracts/48044.htm. Accessed May 21, 2013.
3. J.M. Baeten, D. Donnell, and P. Ndase Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N. Engl. J. Med. 367 2012 399 410
4. I. Batar State-of-the-art of non-hormonal methods of contraception: II. chemical barrier contraceptives Eur. J. Contracept. Reprod. Health Care 15 2010 89 95
5. M.M. Baum, I. Butkyavichene, J. Gilman, S. Kennedy, E. Kopin, A.M. Malone, C. Nguyen, T.J. Smith, D.R. Friend, M.R. Clark, and J.A. Moss An intravaginal ring for the simultaneous delivery of multiple drugs J. Pharm. Sci. 101 2012 2833 2843
6. P. Emau, B. Tian, B.R. O'keefe, T. Mori, J.B. McMahon, K.E. Palmer, Y. Jiang, G. Bekele, and C.C. Tsai Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide J. Med. Primatol. 36 2007 244 253 (Pubitemid 47103488)
7. Facts Consortium FACTS 001 http://www.facts-consortium.co.za/?page-id=83/ 2013
8. J.A. Fernández-Romero, C.J. Abraham, A. Rodriguez, L. Kizima, N. Jean-Pierre, R. Menon, O. Begay, S. Seidor, B.E. Ford, P.I. Gil, J. Peters, D. Katz, M. Robbiani, and T.M. Zydowsky Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge Antimicrob. Agents Chemother. 56 2012 358 368
9. R.M. Grant, J.R. Lama, and P.L. Anderson Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N. Engl. J. Med. 363 2010 2587 2599
10. P.F. Harrison, A. Hemmerling, J. Romano, K.J. Whaley, and B. Young Holt Developing multipurpose reproductive health technologies: an integrated strategy AIDS Res. Treat. 2013 2013 10.1155/2013/790154 Epub 2013 Feb 28
11. R. Heffron, D. Donnell, H. Rees, C. Celum, N. Mugo, E. Were, G. de Bruyn, E. Nakku-Joloba, K. Ngure, J. Kiarie, R.W. Coombs, J.M. Baeten, and Partners in Prevention HSV/HIV Transmission Study Team Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study Lancet Infect. Dis. 12 2012 19 26
12. T.G. Hopkins, and N. Wood Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes Vaccine 31 2013 1673 1679
13. IMPT, 2011. Multipurpose Prevention Technologies for Reproductive Health, 2011 Symposium, Washington DC, Nov 3-4, 2011, Final Report, http://www.cami-health.org/documents/MPT2011-Symposium-Report.pdf.
14. Jackson, A., Else, L., Tja, J., Seymour, N., Stafford, M., Back, D., Gazzard, B., Boffito, M., 2012. Rilpivirine-LA formulation: Pharmacokinetics in plasma, genital tract in HIV- females, and rectum in males. 19th CROI, Abstract 35, March 5-8, 2012, Seattle, WA. http://www.retroconference.org/2012b/ Abstracts/44600.htm.
15. T.J. Johnson, K.M. Gupta, J. Fabian, T.H. Albright, and P.F. Kiser Segmented polyurethane intravaginal rings for sustained combined delivery of antiretroviral agents dapivirine and tenofovir Eur. J. Pharm. 39 2010 203 212
16. Q.A. Karim, S.S.A. Karim, and J.A. Frohlich Effectiveness and safety of tenofovir gel, and anti retroviral microbicide for the prevention of HIV infection in women Science 329 2010 1168 1174
17. S.S.A. Karim, B.A. Richardson, G. Ramjee, I.F. Hoffman, Z.M. Chirenje, T. Taha, M. Kapina, L. Maslankowski, A. Coletti, A. Profy, T.R. Moench, E. Piwowar-Manning, B. Mâsse, S.L. Hillier, and L. Soto-Torres HIV Prevention Trials Network (HPTN) 035 Study Team, Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women AIDS 25 2011 957 966
18. M.J. Keller, A.M. Malone, C.A. Carpenter, Y. Lo, M. Huang, L. Corey, R. Willis, C. Nguyen, S. Kennedy, M. Gunawardana, D. Guerrero, J.A. Moss, M.M. Baum, T.J. Smith, and B.C. Herold Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring J. Antimicrob. Chemother. 67 2012 2005 2012
19. M.M. Lederman, R.S. Veazey, R. Offord, D.E. Mosier, J. Dufour, M. Mefford, M. Piatak Jr, J.D. Lifson, J.R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 Science 306 2004 485 487 (Pubitemid 39372448)
20. F. Lievano, S.A. Galea, and M. Thornton Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience Vaccine 30 2012 6918 6926
21. R.K. Malcolm, S.M. Fetherston, C.F. McCoy, P. Boyd, and I. Major Vaginal rings for delivery of HIV microbicides Intl. J. Women's Health 4 2012 595 605
22. F. Maltêz, M. Doroana, and T. Branco Recent advances in antiretroviral treatment and prevention in HIV-infected patients Curr. Opin. HIV AIDS 6 Suppl 1 2011 S21 S30
23. D. Mansour The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception Contraception 85 2012 224 234
24. D. Marais, D. Gawarecki, B. Allan, K. Ahmed, L. Altini, N. Cassim, F. Gopolang, M. Hoffman, G. Ramjee, and A.L. Williamson The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection Antivir. Ther. 16 2011 1219 1226
25. Marrazzo, J., Ramjee, G., Palanee, T., Mkhize, B., Nakabiito, C., Taljaard, M., Piper, J., Gomez Feliciano, K., Chirenje, M., and VOICE Study Team, 2013. Pre-exposure prophylaxis in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003), 20th CROI, abstract 26LB, March 3-6, 2013, Atlanta, GA. http://www. retroconference.org/2013b/Abstracts/47951.htm.
26. Microbicides Trials Network ASPIRE - A Study to Prevent Infection with a Ring for Extended Use http://www.mtnstopshiv.org/news/studies/mtn020/ backgrounder/ 2013
27. E.T. Montgomery, A. van der Straten, H. Cheng, L. Wegner, G. Masenga, C. von Mollendorf, L. Bekker, S. Ganesh, J. Romano, A. Nel, and C. Woodsong Vaginal ring adherence in sub-Saharan Africa: Expulsion, removal, and perfect use AIDS Behav. 16 2012 1787 1798
28. C.P. Neff, T. Kurisu, T. Ndolo, K. Fox, and R. Akkina A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice PLoS One 6 6 2011 e20209
29. D.J. Smith, S. Wakasiaka, T.D. Hoang, J.J. Bwayo, C. Del Rio, and F.H. Priddy An evaluation of intravaginal rings as potential HIV prevention devices in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk population J. Women's Health 17 2008 1025 1034
30. G.P. Talwar, P. Raghuvanshi, R. Mishra, U. Banerjee, A. Rattan, K.J. Whaley, L. Zeitlin, S.L. Achilles, F. Barré-Sinoussi, A. David, and G.F. Doncel Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens Am. J. Reprod. Immunol. 43 2000 144 151 (Pubitemid 30103453)
31. P.W. Tebbey, and C. Rink Target product profile: a renaissance for its definition and use J. Med. Market. 9 2009 301 307
32. L. Van Damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard, S. Kapiga, M. Malahleha, F. Owino, R. Manongi, J. Onyango, L. Temu, M.C. Monedi, P. Mak'Oketch, M. Makanda, I. Reblin, S.E. Makatu, L. Saylor, H. Kiernan, S. Kirkendale, C. Wong, R. Grant, A. Kashuba, K. Nanda, J. Mandala, K. Fransen, J. Deese, T. Crucitti, T.D. Mastro, R.D. Taylo, and FEM-PrEP study group Preexposure prophylaxis for HIV infection among African women N. Engl. J. Med. 367 2012 411 422
33. A. Van der Straten, E.T. Montgomery, H. Cheng, L. Wegner, G. Masenga, C. von Mollendorf, L. Bekker, S. Ganesh, K. Young, J. Romano, A. Nel, and C. Woodsong High acceptability of a vaginal ring as a microbicide delivery method for HIV prevention in African women AIDS Behav. 16 2012 1775 1786
34. C.E. Von Mollendorf, L. van Damme, J.A. Moyes, V.H. Rees, M.M. Callahan, C.K. Mauck, A.J. Puren, K. Tweedy, and D. Taylor Results of a safety and feasibility study of the diaphragm used with ACIDFORM gel and KY jelly Contraception 81 2010 232 239
35. D.R. Wieder, and L. Pattimakiel Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®) Int. J. Womens Health 2 2010 401 409